IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Serial No.:

Llinas-Brunet, M. et al) Art Unit: 10/091,293 Examiner:

Conf. No.:

03/05/2002

Deborah C. Lambkin

1600 Recept SS co/22 #7

Filed: For:

- 1907

Hepatitis C Inhibitor Tri-Peptides

Docket No.: . 13/068-7-C1

Office of Initial Patent Examination's Customer Service Center Commissioner for Patents Washington, DC 20231

October 7, 2002

REQUEST FOR CORRECTION OF FILING RECEIPT

The undersigned respectfully requests correction of the Filing Receipt for Application Number 10/091,293, Confirmation No. 1907. . A

Please correct the spelling of the last name of the eleventh named applicant from "Wemic" to --Wernic--, as noted on the attached copy of the Official Filing Receipt.

The undersigned hereby requests that the United States Patent and Trademark Office correct its records accordingly and issue a corrected Filing Receipt.

Respectfully submitted,

Philip I. Datlow Attorney for Applicant(s)

Reg. No. 41,482

Patent Department Boehringer Ingelheim Corp. 900 Ridgebury Road, P.O. Box 368 Ridgefield, CT. 06877

Tel.: (203) 798-4542

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Office of Initial Patent Examination's Customer Service Center Commissioner for Patents Washington, DC 20231

on October 7, 2002

Philip I. Datlow Reg. No. 41,482



United States Patent and Trademark Office

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231

CONFIRMATION NO. 1907

FILING RECEIPT

CC00000008731430

Date Mailed: 09/05/2002

28313 BOEHRINGER INGELHEIM CORPORATION 900 RIDGEBURY RD P O BOX 368 RIDGEFIELD, CT 06877

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-748-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if

Applicant(s)

Montse Llinas-Brunet, D.D.O., CANADA; Murray D. Balley, Plerrefonds, CANADA; Date R. Cameron, Rosemere, CANADA; Elise Ghiro, Laval, CANADA; Nathalie Goudreau, Mont-Royal, CANADA; Marc-Andre Poupent, Vimont, CANADA; Jean Rancourt, Laval, CANADA; Youle S. Tsantrizos, Saint-Laurent, CANADA; Anne-Marie Faucher, Oka, CANADA; Teddy Halmos, Laval, CANADA;

Wernic

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A CON OF 09/849,057 05/04/2001 PAT 6,410,531 WHICH IS A DIV OF 09/368,866 08/05/1999 PAT 6,323,180 WHICH CLAIMS BENEFIT OF 60/095,931 08/10/1998 AND CLAIMS BENEFIT OF 60/132,386 05/04/1999

Foreign Applications

If Required, Foreign Filing License Granted 05/16/2002

Projected Publication Date: 08/22/2002





Non-Publication Request: No

Early Publication Request: No

Title

Hepatitis C inhibitor tri-peptides

Preliminary Class

514

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in applications where the conditions for Issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 of 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to esplonage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (iii); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 5004) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, If a license is desired before the expiration of 6 months from the filling date of the application. If 6 months has lapsed from the filling date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

